@AACR Top Trials from Day 4

AACR 2026 现场信号· @ · X·2026-04-22 03:27· 2026-04-22评分60

正文 · 机器翻译

热度 2 · 1 赞 · 0 回复 · 1 转发

会议摘要

CT028NCT06237881按 NCT NCT06237881 对上

Results of first-in-human, Phase 1 study of KSQ-001EX, an autologous tumor infiltrating lymphocyte therapy engineered to inactivate the SOCS1 gene, in patients with select advanced solid tumors

Rodabe N. Amaria, Hussein A. Tawbi, Alexandra Ikeguchi, Isabella C. Glitza-Oliva, Jennifer L. McQuade, Michael A. Davies, Youlia Petrova, Cara Haymaker, Chantale Bernatchez, Marie-Andree Forget, Karrie Wong, Erica R. Tobin, Micah J. Benson, Anna Truppel-Hartmann, Patricia M. Harris

读摘要原文 →

3721NCT06237881按 NCT NCT06237881 对上

Anti-tumor function and long-term persistence of KSQ-001EX, a SOCS1-edited eTIL® therapy, independent of IL-2 co-administration

Dipen Sangurdekar, Erica Tobin, Karrie Wong, Ashish Yeri, Alex Smashnov, Kelly Bowen, Giorgio Sarkis, Violetta Medik, Hsinyi Lu, Sevinj Isgandarova, Michelle Carrasco, Patricia Harris, Cara L. Haymaker, Micah Benson, Anna Truppel-Hartmann, Rodabe N. Amaria

读摘要原文 →

来源：AACR 2026 现场信号 · x.com